- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- CNS cancers
- Leukemias, lymphomas, and other hematologic cancers
Bladder, kidney, and other urologic cancers:
Indications for: Vincristine Sulfate PFS
In combination with other chemotherapeutic agents for Wilms' tumor.
Adult Dosage:
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
Children Dosage:
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Vincristine Sulfate PFS Contraindications:
Demyelinating form of Charcot-Marie-Tooth syndrome.
Boxed Warning:
Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).
Vincristine Sulfate PFS Warnings/Precautions:
Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Vincristine Sulfate PFS Classification:
Antimicrotubule agent.
Vincristine Sulfate PFS Interactions:
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
Adverse Reactions:
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Note:
Formerly known under the brand name Vincasar PFS.
How Supplied:
Contact supplier
Bone and connective tissue cancer:
Indications for: Vincristine Sulfate PFS
In combination with other chemotherapeutic agents for rhabdomyosarcoma.
Adult Dosage:
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
Children Dosage:
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Vincristine Sulfate PFS Contraindications:
Demyelinating form of Charcot-Marie-Tooth syndrome.
Boxed Warning:
Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).
Vincristine Sulfate PFS Warnings/Precautions:
Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Vincristine Sulfate PFS Classification:
Antimicrotubule agent.
Vincristine Sulfate PFS Interactions:
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
Adverse Reactions:
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Note:
Formerly known under the brand name Vincasar PFS.
How Supplied:
Contact supplier
CNS cancers:
Indications for: Vincristine Sulfate PFS
In combination with other chemotherapeutic agents for neuroblastoma.
Adult Dosage:
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
Children Dosage:
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Vincristine Sulfate PFS Contraindications:
Demyelinating form of Charcot-Marie-Tooth syndrome.
Boxed Warning:
Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).
Vincristine Sulfate PFS Warnings/Precautions:
Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Vincristine Sulfate PFS Classification:
Antimicrotubule agent.
Vincristine Sulfate PFS Interactions:
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
Adverse Reactions:
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Note:
Formerly known under the brand name Vincasar PFS.
How Supplied:
Contact supplier
Leukemias, lymphomas, and other hematologic cancers:
Indications for: Vincristine Sulfate PFS
Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types).
Adult Dosage:
Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.
Children Dosage:
≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.
Vincristine Sulfate PFS Contraindications:
Demyelinating form of Charcot-Marie-Tooth syndrome.
Boxed Warning:
Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).
Vincristine Sulfate PFS Warnings/Precautions:
Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Vincristine Sulfate PFS Classification:
Antimicrotubule agent.
Vincristine Sulfate PFS Interactions:
Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.
Adverse Reactions:
GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.
Note:
Formerly known under the brand name Vincasar PFS.
How Supplied:
Contact supplier
